The Problem
The evolution and spread and antibiotic resistance in pathogenic bacteria poses an alarming threat to human life in its potential to make obsolete that which is arguably the greatest medical achievement of the last century: the discovery and development of antibiotics.
Our Research Question
Can we effectively target antibiotic resistance genes in nalidixic acid resistant Escherichia coli using a CRISPR-Cas9 gene editing system delivered via bacteriophage M13? Can we edit those genes precisely?
Our Mission
Our team is working to perform a proof-of-concept experiment in nalidixic acid resistant Escherichia coli in order to work towards the establishment of phage-delivered CRISPR systems as a treatment option for antibiotic resistant infections.
